|
|
|
Volumn 21, Issue 2, 2002, Pages 177-180
|
|
A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC)
a
|
|
Author keywords
Hormone resistant; Palliation; Single agent chemotherapy
|
|
Indexed keywords
IFOSFAMIDE;
PROSTATE SPECIFIC ANTIGEN;
ALKYLATING AGENT;
ADULT;
AGED;
ANGINA PECTORIS;
ARTICLE;
BLOOD TOXICITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GROWTH;
CANCER PALLIATIVE THERAPY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOSE CALCULATION;
DRUG TOLERABILITY;
HORMONE REFRACTORY PROSTATE CANCER;
HUMAN;
LEUKOPENIA;
MALE;
METASTASIS;
PHASE 2 CLINICAL TRIAL;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROSTATE CARCINOMA;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL TIME;
TREATMENT OUTCOME;
ADENOCARCINOMA;
BLOOD;
BONE TUMOR;
DISEASE COURSE;
DOSE RESPONSE;
INTRAVENOUS DRUG ADMINISTRATION;
MIDDLE AGED;
PATHOLOGY;
PROSTATE TUMOR;
SAFETY;
SURVIVAL RATE;
ADENOCARCINOMA;
AGED;
ANTINEOPLASTIC AGENTS, ALKYLATING;
BONE NEOPLASMS;
DISEASE PROGRESSION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HUMAN;
IFOSFAMIDE;
INFUSIONS, INTRAVENOUS;
MALE;
MIDDLE AGE;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
SAFETY;
SURVIVAL RATE;
HUMANS;
MIDDLE AGED;
|
|
EID: 0035991490
PISSN: 03929078
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (17)
|
